Novartis receives EU approval for Bexsero®
22 January 2013 | By Novartis
Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe...
List view / Grid view
22 January 2013 | By Novartis
Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe...
18 January 2013 | By Novartis
"Novartis welcomes the decision by the CHMP in support of the approval of Ilaris in the EU"
18 January 2013 | By Novartis
Jetrea(TM) would become the first drug to treat sight-threatening vitreomacular traction and macular hole...
17 January 2013 | By Novartis
"The challenges in delivering healthcare in developing countries are considerable..."
14 January 2013 | By Novartis
Findings from a pivotal Phase III clinical trial...
11 January 2013 | By Novartis
Data published today...
21 December 2012 | By Novartis
The EC has approved Exjade®...
15 December 2012 | By Novartis
The US FDA has approved Signifor®...
11 December 2012 | By Novartis
Novartis announced long-term follow-up data...
10 December 2012 | By Novartis
Latest results from two Phase III clinical trials...
4 December 2012 | By Novartis
Healthcare experts assess psychosocial approaches and interventions...
28 November 2012 | By Novartis
More than 140 presentations on key data...
20 November 2012 | By Novartis
The US FDA approved the use of Flucelvax®...
16 November 2012 | By Novartis
The CHMP of the EMA adopted a positive opinion for Exjade®...
16 November 2012 | By Novartis
The CHMP of the EMA has adopted a positive opinion for Bexsero for use in individuals from 2 months of age and older...